Claims for Patent: 8,790,646

Summary for Patent: 8,790,646

Title:	Compositions and methods for modulating vascular development
Abstract:	The present invention provides methods of using EGFL7 antagonist to modulate vascular development. Also provided herein are methods of screening for modulators of EGFL7 activity. Furthermore, methods of treatment using EGFL7 antagonists are provided.
Inventor(s):	Filvaroff; Ellen (San Francisco, CA), Ye; Weilan (Foster City, CA), Parker, IV; Leon H. (San Francisco, CA), Hongo; Jo-Anne S. (Redwood City, CA), Schmidt; Maike (San Francisco, CA)
Assignee:	Genentech Inc. (South San Francisco, CA)
Application Number:	12/904,813
Patent Claims:	1. A method of reducing or inhibiting angiogenesis in a subject having a pathological condition associated with angiogenesis, comprising administering to the subject an EGFL7 antagonist capable of interfering with EGFL7-induced vascular tube formation, thereby reducing or inhibiting angiogenesis in the subject, wherein the EGFL7 antagonist is an anti-EGFL7 antibody. 2. The method of claim 1, wherein the pathological condition is a neoplasm. 3. The method of claim 2, wherein the neoplasm is a carcinoma. 4. The method of claim 1, wherein the pathological condition is associated with the eye. 5. The method of claim 4, wherein the pathological condition is an intraocular neovascular disease. 6. The method of claim 1, further comprising administering to the subject an anti-angiogenic agent. 7. The method of claim 6, wherein the anti-angiogenic agent is administered prior to or subsequent to the administration of the EGFL7 antagonist. 8. The method of claim 6, wherein the anti-angiogenic agent is administered concurrently with the EGFL7 antagonist. 9. The method of claim 6, wherein the anti-angiogenic agent is an antagonist of vascular endothelial cell growth factor (VEGF). 10. The method of claim 9, wherein the VEGF antagonist is an anti-VEGF antibody. 11. The method of claim 10, wherein the anti-VEGF antibody is bevacizumab. 12. The method of claim 1, wherein the EGFL7 antagonist's ability to interfere with EGFL7-induced endothelial cell migration is detected in an in vitro cell migration assay. 13. A method of enhancing efficacy of an anti-angiogenic agent in a subject having a pathological condition associated with angiogenesis, comprising administering to the subject an EGFL7 antagonist in combination with the anti-angiogenic agent capable of inhibiting angiogenesis, thereby enhancing said anti-angiogenic agent's inhibitory activity, wherein the EGFL7 antagonist is an anti-EGFL7 antibody capable of interfering with EGFL7-induced vascular tube formation. 14. The method of claim 13, wherein the pathological condition is a neoplasm. 15. The method of claim 14, wherein the neoplasm is a carcinoma. 16. The method of claim 13, wherein the pathological condition is associated with the eye. 17. The method of claim 16, wherein the pathological condition is an intraocular neovascular disease. 18. The method of claim 15, further comprising administering a chemotherapeutic agent.

Details for Patent 8,790,646

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2024-04-14